Incyte is sticking to its strategy this year of finding “early-stage, exotic stuff”—paying Genesis Therapeutics $30 million upfront to use the biotech’s artificial intelligence platform to ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Some scientists are confident that organs from genetically modified pigs will one day be routinely transplanted into humans.

About Genesis Therapeutics Genesis Therapeutics, Inc. is an AI-focused biotechnology company leveraging its generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space ...

Stereotaxis targets growth with 2025 product milestones, MAGiC Sweep revenue, and EMAGIN 5F innovation, setting the stage for ...

Inhwa Yeom uses XR and AI to create artworks offering social commentary; catch her at the Hong Kong Arts Centre’s ‘Future Tense’ exhibition.

Ralston brings more than 25 years of experience providing strategic Market Access and HEOR solutions.

We recently published a list of 12 AI Updates Worth Taking a Look At. In this article, we are going to take a look at where ...

LONDON, March 3, 2025 /PRNewswire/ -- Coronado Research, a consultancy-led, professional services organisation providing support to pharmaceutical, biotechnology ... at companies including Genesis ...

US biopharma Incyte (Nasdaq: INCY) and privately-held AI-focused biotech Genesis Therapeutics have entered into a strategic collaboration focused on the research, discovery and development of novel ...